Skip to content

Study · Randomized controlled trial · 2016

2 results

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH

Arteriosclerosis, thrombosis, and vascular biology25 Aug 2016Cited by 27 (Europe PMC)

PMID27562916 (opens in a new tab)DOI10.1161/atvbaha.116.307930 (opens in a new tab)PepBankPUB-27562916
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 12 weeks of liraglutide had no effect on skin capillary perfusion versus placebo.

    In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change blood flow in the smallest skin vessels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCapillary perfusion (fasting and postprandial)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Twelve-week treatment with liraglutide or sitagliptin has no effect on capillary perfusion or vasomotion in these patients.
    3 context sentences
    Summary · context
    In neither study, treatment affected fasting or postprandial capillary perfusion compared with placebo (P>0.05).
    Summary · context
    We studied 57 patients with type 2 diabetes mellitus (mean±SD age: 62.8±6.9 years; body mass index: 31.8±4.1 kg/m(2); HbA1c [glycated hemoglobin] 7.3±0.6%) in an acute and 12-week randomized, placebo-controlled, double-blind trial conducted at the Diabetes Center of the VU University Medical Center.
    Summary · context
    During the 12-week study, patients received the GLP-1 receptor agonist liraglutide (1.8 mg daily), the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg daily), or matching placebos.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 12 weeks of liraglutide had no effect on skin vasomotion versus placebo.

    In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change small-vessel rhythm in the skin compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeVasomotion
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Twelve-week treatment with liraglutide or sitagliptin has no effect on capillary perfusion or vasomotion in these patients.
    3 context sentences
    Summary · context
    In the 12-week study, no effects on vasomotion were observed.
    Summary · context
    We studied 57 patients with type 2 diabetes mellitus (mean±SD age: 62.8±6.9 years; body mass index: 31.8±4.1 kg/m(2); HbA1c [glycated hemoglobin] 7.3±0.6%) in an acute and 12-week randomized, placebo-controlled, double-blind trial conducted at the Diabetes Center of the VU University Medical Center.
    Summary · context
    During the 12-week study, patients received the GLP-1 receptor agonist liraglutide (1.8 mg daily), the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg daily), or matching placebos.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.